A Study of CS1001 in Subjects With Gastric Adenocarcinoma or Gastro-Esophageal Junction Adenocarcinoma

NCT03802591 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

479

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastric Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG: CS1001 monoclonal antibody
DRUG: CS1001 placebo
DRUG: Oxaliplatin
DRUG: Capecitabine

Sponsor

CStone Pharmaceuticals